Ładuje się......
Golimumab in the treatment of ulcerative colitis
Golimumab was approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of moderate-to-severe ulcerative colitis in 2013 and was the third antitumour-necrosis-factor therapy after adalimumab and infliximab licensed for this indication. However, given it is t...
Zapisane w:
| Wydane w: | Therap Adv Gastroenterol |
|---|---|
| Główni autorzy: | , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
SAGE Publications
2019
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6351715/ https://ncbi.nlm.nih.gov/pubmed/30728858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284818821266 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|